PT - JOURNAL ARTICLE AU - Zhang, Chao AU - Tang, Wenjuan AU - Cheng, Liang AU - Yang, Chen AU - Wang, Ting AU - Wang, Juan AU - Miao, Zhuang AU - Zhao, Xintong AU - Fang, Xinggen AU - Zhou, Yunfeng TI - Prediction and prognosis of delayed cerebral ischemia via continuous monitoring of blood-brain barrier permeability AID - 10.1101/2023.02.12.23285830 DP - 2023 Jan 01 TA - medRxiv PG - 2023.02.12.23285830 4099 - http://medrxiv.org/content/early/2023/02/16/2023.02.12.23285830.short 4100 - http://medrxiv.org/content/early/2023/02/16/2023.02.12.23285830.full AB - Background Blood-brain barrier disruption is a prominent pathological characteristic of aneurysmal subarachnoid hemorrhage (aSAH), which can be measured as Ktrans using CT perfusion.Purpose To monitor Ktrans within 24 hours of aSAH and during the time window associated with a delayed cerebral ischemia (DCI) event (DCITW), and to explore its association with the trajectory of DCI, including outcome at three months.Methods We retrospectively assessed consecutive aSAH patients from a prospective database between July 2020 and September 2022. Patients were grouped according to the DCI occurrence and three months modified Rankin scale. Ktrans at admission (admission Ktrans) and during DCITW (DCITW Ktrans) were compared between DCI and non-DCI groups, and between good outcome and poor outcome groups. The changes in Ktrans were also analyzed. Multivariate logistic regression analysis was performed to identify independent predictors of DCI and poor outcome.Results One hundred and twenty-eight patients (mean age, 61±12 [SD]; 75 women) were included. Both admission Ktrans (0.58±0.18 vs 0.47±0.12, P=0.002) and DCITW Ktrans (0.54±0.19 vs 0.41±0.14, P<0.001) were significantly higher in the DCI group compared with the non-DCI group. Both of those were also higher in the poor outcome group compared with the good outcome group, but the difference was not statistically significant at admission (0.53±0.18 vs0.49±0.14, P=0.198). Ktrans in the non-DCI group (0.47±0.12 vs 0.41±0.14, P=0.004) and good outcome group (0.49±0.14 vs 0.41±0.14, P<0.001) decreased significantly from admission to DCITW. Multivariate analysis identified DCITW Ktrans and admission Ktrans as independent predictors of poor outcome (OR=1.73, 95%CI: 1.24-2.43, P=0.001) and DCI (OR=1.75, 95%CI: 1.25-2.44, P=0.001), respectively.Conclusion Elevated Ktrans at admission is associated with the occurrence of DCI, but not with outcome at three months. Continuous monitoring of Ktrans from admission to DCITW can accurately identify reversible and irreversible changes in Ktrans, and can predict outcome.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis study was a retrospective study.Clinical Protocols None None Funding StatementChao Zhang received funding from 2022 Young and Middle-Aged Research Fundation in Wannan Medical College (WK2022F33), Dr Yunfeng Zhou from Yijishan Hospital of Wannan Medical College (KGF2019G13).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This retrospective study was approved by the institutional review board of Yijishan Hospital of Wannan Medical College.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Not ApplicableThe data supporting the study findings are available upon reasonable request. None None aSAHaneurysmal subarachnoid hemorrhage,BBBblood-brain barrier,BBBPblood-brain barrier permeability,DCIdelayed cerebral ischemia,DCITWtime window of delayed cerebral ischemia,H-HHunt-Hess grade,mFSmodified Fisher Score,SEBESSubarachnoid Hemorrhage Early Brain Edema Score,WFNSWorld Federation of Neurosurgery Scale